Revisiting the role of antiandrogen strategies in ovarian cancer

Oncologist

Volumn 16, Issue 10, 2011, Pages 1413-1421

  Papadatos Pastos, Dionysis ^a   Dedes, Konstantin J ^a   de Bono, Johann S ^a   Kaye, Stanley B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Abiraterone; Androgen receptor; Consolidation treatment; Endocrine treatment; Ovarian cancer

Indexed keywords

ABIRATERONE; AMPLIFIED IN BREAST 1 PROTEIN; ANASTROZOLE; ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ASSOCIATED PROTEIN 70; ANTIANDROGEN; BICALUTAMIDE; CA 125 ANTIGEN; CYTOCHROME P450 17; CYTOCHROME P450 17A1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; FLUTAMIDE; FOLLITROPIN; GENE PRODUCT; GONADORELIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN; GOSERELIN; GUANOSINE TRIPHOSPHATASE; LETROZOLE; LUTEINIZING HORMONE; RAB35 PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRINUCLEOTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANDROGEN RECEPTOR GENE; ANTIANDROGEN THERAPY; AROMATIZATION; BODY MASS; BREAST CANCER; CANCER INHIBITION; CANCER RISK; DRUG MECHANISM; EPITHELIAL OVARIAN CANCER; ESTROGEN SYNTHESIS; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; INTRACELLULAR SIGNALING; LOW DRUG DOSE; METASTASIS; OBESITY; OVARY CANCER; OVARY POLYCYSTIC DISEASE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TRINUCLEOTIDE REPEAT;

ANDROGEN ANTAGONISTS; ANDROGENS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 80054813459     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0164     Document Type: Review

References (85)

1. Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary. Biol Reprod 2008;78:380-389.
2. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell 2009;16:458-462.
3. Bennett NC, Gardiner RA, Hooper JD et al. Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol 2010;42:813-827.
4. van Doorn HC, Burger CW, van der Valk P et al. Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: Correlation between immunohistochemical and biochemical receptor analyses. J Clin Pathol 2000;53: 201-205.
5. Burger HG. Androgen production in women. Fertil Steril 2002;77(suppl 4): S3-S5.
6. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-1786.
7. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
8. Schildkraut JM, Schwingl PJ, Bastos E et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88:554-559.
9. Olsen CM, Green AC, Nagle CM et al. Epithelial ovarian cancer: Testing the 'androgens hypothesis.' Endocr Relat Cancer 2008;15:1061-1068.
10. Folsom AR, Kushi LH, Anderson KE et al. Associations of general and abdominal obesity with multiple health outcomes in older women: The Iowa Women's Health Study. Arch Intern Med 2000;160:2117-2128.
11. Huang Z, Hankinson SE, Colditz GA et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-1411.
12. Olsen CM, Green AC, Whiteman DC et al. Obesity and the risk of epithelial ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 2007; 43:690-709.
13. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
14. Engeland A, Tretli S, Bjørge T. Height, body mass index, and ovarian cancer: Afollow-up of 1.1 million Norwegian women. J Natl Cancer Inst 2003; 95:1244-1248.
15. Pan SY, Johnson KC, Ugnat AM et al. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004;159:259-268.
16. Wolk A, Gridley G, Svensson M et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21.
17. Lahmann PH, Cust AE, Friedenreich CM et al. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010;126:2404-2415.
18. Cottreau CM, Ness RB, Modugno F et al. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin Cancer Res 2003; 9:5142-5144.
19. Giovannucci E, Stampfer MJ, Krithivas K et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320-3323.
20. Chamberlain NL, Driver ED, Miesfeld RL. The length and location ofCAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181-3186.
21. Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: Possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 1995;4:523-527.
22. Buchanan G, Yang M, Cheong A et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 2004;13:1677-1692.
23. Lindström S, Ma J, Altshuler D et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab 2010; 95;E121-E127.
24. Price DK, Chau CH, Till C et al. Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Urol 2010;184:2297-2302.
25. Rodriguez-Gonzalez G, Cabrera S, Ramirez-Moreno R et al. Short alleles of both GGN and CAG repeats at the exon-1 of the androgen receptor gene are associated to increased PSA staining and a higher Gleason score in human prostatic cancer. J Steroid Biochem Mol Biol 2009;113:85-91.
26. Ludwig AH, Murawska M, Panek G et al. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer 2009;16:1005-1016.
27. Terry KL, De Vivo I, Titus-Ernstoff L et al. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 2005;65:5974-5981.
28. Li AJ, Baldwin RL, Karlan BY. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res 2003;9:3667-3673.
29. Li AJ, Elmore RG, Pavelka JC et al. Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol 2007;107:420-423.
30. Garner EI, Stokes EE, Berkowitz RS et al. Polymorphisms of the estrogenmetabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002;62:3058-3062.
31. Haiman CA, Hankinson SE, Spiegelman D et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999;59:1015-1020.
32. Nagle CM, Chenevix-Trench G, Webb PM et al. Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes. Cancer Lett 2007;251:96-104.
33. Dunning AM, Dowsett M, Healey CS et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-945.
34. Anzick SL, Kononen J, Walker RL et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-968.
35. Shaw PA, Rittenberg PV, Brown TJ. Activation of androgen receptorassociated protein 70 (ARA70) mRNA expression in ovarian cancer. Gynecol Oncol 2001;80:132-138.
36. Tanner MM, Grenman S, Koul A et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000;6:1833-1839.
37. Li AJ, Lerner DL, Gapuzan ME et al. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev 2005; 14:2919-2922.
38. Evangelou A, Jindal SK, Brown TJ et al. Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 2000;60:929-935.
39. Havrilesky LJ, Hurteau JA, Whitaker RS et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res 1995;55:944-948.
40. Evangelou A, Letarte M, Jurisica I et al. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells. Cancer Res 2003;63:2416-2424.
41. Carey MS, Agarwal R, Gilks B et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 2010;16:2852-2860.
42. Do TV, Kubba LA, Du H et al. Transforming growth factor-_1, transforming growth factor-_2, and transforming growth factor-_3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-tomesenchymal transition. Mol Cancer Res 2008;6:695-705.
43. Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 2010;277:309-315.
44. Hudson LG, Moss NM, Stack MS. EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncol 2009;5:323-338.
45. Stadlmann S, Gueth U, Reiser U et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006;19:607-610.
46. Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: A potential molecular switch for tumour growth. Br J Cancer 2009;101:1949-1956.
47. Ilekis JV, Connor JP, Prins GS et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997;66:250-254.
48. Li AJ, Scoles DR, Armstrong KU et al. Androgen receptor cytosine-ade- nine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol 2008;109:220-225.
49. Sheach LA, Adeney EM, Kucukmetin A et al. Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 2009;101:498-503.
50. Nourbakhsh M, Golestani A, Zahrai M et al. Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol 2010;330:10-16.
51. Parmar H, Phillips RH, Rustin G et al. Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother 1988;42:531-538.
52. Kavanagh JJ, Roberts W, Townsend P et al. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989;7:115-118.
53. Lind MJ, Cantwell BM, Millward MJ et al. A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 1992;65:621-623.
54. Miller DS, Brady MF, Barrett RJ. A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 1992;15:125-128.
55. Carnino F, Iskra L, Fuda G et al. The treatment of progressive ovarian carcinoma with D-Trp-LHRH (Decapeptyl). Gruppo Oncologico Nord Ovest (GONO). Eur J Cancer 1994;30A;1903-1904.
56. Marinaccio M, D'Addario V, Serrati A et al. Leuprolide acetate as a salvage- therapy in relapsed epithelial ovarian cancer. Eur J Gynaecol Oncol 1996;17:286-288.
57. Jager W, Sauerbrei W, Beck E et al. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res 1995;15:2639-2642.
58. Ron IG, Wigler N, Merimsky O et al. A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest 1995;13:272-275.
59. Duffaud F, van der Burg ME, NamerMet al. D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: An EORTC Gynaecological Cancer Co-operative Group study. Anticancer Drugs 2001;12:159-162.
60. Paskeviciute L, Roed H, Engelholm S. No rules without exception: Longterm complete remission observed in a study using a LH-RH agonist in platinum- refractory ovarian cancer. Gynecol Oncol 2002;86:297-301.
61. du Bois A, Meier W, Lück HJ et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: A randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 2002;13:251-257.
62. Balbi G, Piano LD, Cardone A et al. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 2004;14:799-803.
63. Kang SK, Cheng KW, Nathwani PS et al. Autocrine role of gonadotropinreleasing hormone and its receptor in ovarian cancer cell growth. Endocrine 2000;13:297-304.
64. Radu A, Pichon C, Camparo P et al. Expression of follicle-stimulating hormone receptor in tumour blood vessels. N Engl J Med 2010;363:1621-1630.
65. Tumolo S, Rao BR, van der Burg ME et al. Phase II trial of flutamide in advanced ovarian cancer: An EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer 1994;30A;911-914.
66. Vassilomanolakis M, Koumakis G, Barbounis V et al. A phase II study of flutamide in ovarian cancer. Oncology 1997;54:199-202.
67. Hasan J, Ton N, Mullamitha S et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer 2005;93:647-651.
68. Hofstra LS, Mourits MJ, de Vries EG et al. Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Anticancer Res 1999;19:3627-3630.
69. Levine D, Park K, Juretzka M et al. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007;110:2448-2456.
70. Barrie SE, Potter GA, Goddard PM et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-273.
71. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009;100:671-675.
72. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;21:1995-2005.
73. Basu B, Ang J, Blanco M et al. Preliminary report of efficacy of abiraterone acetate in patients with estrogen (ER) or androgen receptor (AR) positive, advanced breast carcinoma resistant to standard endocrine therapies. Presented at the 2010 European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium, Berlin, Germany, November 16-19, 2010.
74. Banerjee S, Gore M. The future of targeted therapies in ovarian cancer. The Oncologist 2009;14:706-716.
75. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-2519.
76. Bowman A, Gabra H, Langdon SP et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:2233-2239.
77. Papadimitriou CA, Markaki S, Siapkaras J et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer: Long-term results of a phase II study. Oncology 2004;66:112-117.
78. Smyth JF, Gourley C, Walker G et al. Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptorpositive patients. Clin Cancer Res 2007;13:3617-3622.
79. del Carmen MG, Fuller AF, Matulonis U et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 2003;91: 596-602.
80. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000;7:85-93.
81. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-1501.
82. Jonat W, Howell A, Blomqvist C et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A;404-412.
83. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-1411.
84. Kvinnsland S, Anker G, Dirix LY et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000;36:976-982.
85. Mauriac L, Pippen JE, Quaresma Albano J et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003; 39:1228-1233.